2',3'-Dideoxyadenosine

Suppliers

Names

[ CAS No. ]:
4097-22-7

[ Name ]:
2',3'-Dideoxyadenosine

[Synonym ]:
DDA
((2S,5R)-5-(6-Amino-9H-purin-9-yl)tetrahydrofuran-2-yl)methanol
[(2S,5R)-5-(6-aminopurin-9-yl)oxolan-2-yl]methanol
Dideoxyadenosine
Didanosine impurity G
6-Amino-9-(2',3'-dideoxy-b-D-glycero-pentofuranosyl)purine
EINECS 223-853-2
[(2S,5R)-5-(6-Amino-9H-purin-9-yl)tetrahydrofuran-2-yl]methanol
2-furanmethanol, 5-(6-amino-9H-purin-9-yl)tetrahydro-, (2S,5R)-
2',3'-Dideoxyadenosine
9-(2,3-Dideoxy-β-D-ribofuranosyl)adenine
MFCD00010534
9-(2,3-Dideoxy-beta-D-ribofuranosyl)adenine
[(2S,5R)-5-(6-Amino-9H-purin-9-yl)tetrahydro-2-furanyl]methanol

Chemical & Physical Properties

[ Density]:
1.8±0.1 g/cm3

[ Boiling Point ]:
539.1±60.0 °C at 760 mmHg

[ Melting Point ]:
181-184 °C(lit.)

[ Molecular Formula ]:
C10H13N5O2

[ Molecular Weight ]:
235.242

[ Flash Point ]:
279.9±32.9 °C

[ Exact Mass ]:
235.106918

[ PSA ]:
99.08000

[ LogP ]:
-0.43

[ Vapour Pressure ]:
0.0±1.5 mmHg at 25°C

[ Index of Refraction ]:
1.822

[ Storage condition ]:
2-8°C

MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
AU7358900
CHEMICAL NAME :
Adenosine, 2',3'-dideoxy-
CAS REGISTRY NUMBER :
4097-22-7
BEILSTEIN REFERENCE NO. :
0619924
LAST UPDATED :
199612
DATA ITEMS CITED :
11
MOLECULAR FORMULA :
C10-H13-N5-O2
MOLECULAR WEIGHT :
235.28

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1320 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
19600 mg/kg/28D-I
TOXIC EFFECTS :
Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Blood - changes in erythrocyte (RBC) count Nutritional and Gross Metabolic - weight loss or decreased weight gain

MUTATION DATA

TEST SYSTEM :
Rodent - mouse
DOSE/DURATION :
9 gm/kg/3D (Continuous)
REFERENCE :
EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987- Volume(issue)/page/year: 18,168,1991

Safety Information

[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ Hazard Codes ]:
C

[ Risk Phrases ]:
R34

[ Safety Phrases ]:
26-27-36/37/39-45

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
2

[ RTECS ]:
AU7358900

[ HS Code ]:
2934999090

Synthetic Route

Precursor & DownStream

Precursor

  • beta-L-D4A
  • 6H-Purin-6-imine, 1,7-dihydro- (9CI)
  • 2',3'-Dideoxyuridine
  • (2R,3R,4R,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diyl dimethanesulfonate
  • Adenosine
  • (5S)-5-(Hydroxymethyl)dihydro-2(3H)-furanone
  • 5'-O-[(1,1-dimethylethyl)dimethylsilyl]adenosine

DownStream

  • 2',3'-Dideoxyinosine
  • 2',3'-Dideoxyadenosine
  • [(2S,5R)-5-purin-9-yloxolan-2-yl]methanol
  • [(2S,5R)-5-(6-amino-8-bromopurin-9-yl)oxolan-2-yl]methanol

Customs

[ HS Code ]: 2934999090

[ Summary ]:
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Articles

RGS19 converts iron deprivation stress into a growth-inhibitory signal

Biochem. Biophys. Res. Commun. 464 , 168-75, (2015)

Iron chelation is a promising therapeutic strategy for cancer that works, in part, by inducing overexpression of N-myc downstream-regulated gene 1 protein (NDRG1), a known growth inhibitor and metasta...

The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients.

Cancer Res. 75(1) , 16-21, (2015)

Identifying modifiers of glioma risk in patients with type I neurofibromatosis (NF1) could help support personalized tumor surveillance, advance understanding of gliomagenesis, and potentially identif...

Metformin as adjunct antituberculosis therapy.

Sci. Transl. Med. 6(263) , 263ra159, (2014)

The global burden of tuberculosis (TB) morbidity and mortality remains immense. A potential new approach to TB therapy is to augment protective host immune responses. We report that the antidiabetic d...


More Articles


Related Compounds

  • iso-2',3'-dideoxyadenosine
  • 2-Iodo-2',3'-dideoxyadenosine
  • 3-Deaza-2',3'-dideoxyadenosine
  • 8-Amino-2',3'-dideoxyadenosine
  • 4'-Thio-2',3'-dideoxyadenosine
  • 7-Deaza-2',3'-dideoxyadenosine